Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
January 09, 2023 at 09:00 AM EST
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21
-- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21
-- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio’s SOLA platform for enzymatic DNA synthesis technology
SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022. The results are subject to the completion of the Company’s year-end financial reporting processes, reviews, and audit. Telesis Bio also announced that it has achieved the first technical milestone under its 2022 Collaboration and Licensing Agreement with Pfizer to further develop SOLA, Telesis Bio’s novel enzymatic DNA synthesis (EDS) technology for Pfizer’s use in its research and development of mRNA-based vaccines and biotherapies.
“We are grateful to our Telesis Bio team for their tremendous efforts resulting in a stellar 2022 where we exceeded revenue expectations, delivered meaningful expansion of gross margin due to favorable product mix and cost stabilization and importantly, delivered key products for our customers and achieved milestones for our partners,” said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio. “We are excited for what is ahead in 2023 and executing on our identified path to achieve positive cash flow by 2H 2024.”
About Telesis Bio
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.